AJANTPHARM2021-07-012021-09-30in-bse-fin:OneOperatingExpenses01Member AJANTPHARM2021-07-012021-09-30in-bse-fin:FourOperatingExpenses01Member AJANTPHARM2021-07-012021-09-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member AJANTPHARM2021-07-012021-09-30in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member AJANTPHARM2021-07-012021-09-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member AJANTPHARM2021-07-012021-09-30in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares AJANTPHARM 2021-04-01 2022-03-31 2021-10-21 INR Crores Half yearly true Cash Flow Indirect Single segment PHARMACEUTICAL 2021-07-01 2021-09-30 Unaudited Consolidated 8848000000.00 295400000.00 9143400000.00 1741000000.00 380800000.00 200500000.00 1600800000.00 4000000.00 315400000.00 2296700000.00 6539200000.00 2604200000.00 0.00 2604200000.00 699900000.00 -55100000.00 644800000.00 0.00 1959400000.00 0.00 0.00 0.00 0.00 1959400000.00 -42500000.00 1916900000.00 0.00 0.00 1916900000.00 0.00 173900000.00 2 22.64 22.64 0.00 0.00 22.64 22.64 1. The above consolidated unaudited financial results have been reviewed by Audit Committee and approved by the Board of Directors at their meeting held on 29 October 2021. The statutory auditors have expressed unmodified opinion. The review report has been filed with the stock exchange and is available on company website. 2. Board of Directors have approved payment of interim dividend on 29 October 2021 of Rs. 9.50 per equity share of face value of Rs. 2 each. 3. The consolidated unaudited financial results of the Company, its wholly owned subsidiaries and step-down subsidiary (“the Group”) have been prepared as per Ind AS 110 on Consolidated Financial Statements. There is no minority interest. 4. The Group continued to take into account the possible impacts of COVID-19 in preparation of the financial statements, including but not limited to its assessment of liquidity and going concern assumption, recoverable values of its financial and non-financial assets, impact on revenues and on costs. The Group has been able to effectively manage the operations till now with appropriate safety precautions, without any significant impact of COVID-19 on the business. The Group will continue to closely monitor future economic conditions to ensure business continuity. 5. During the quarter 4,000 equity shares (previous year Nil) of Rs. 2 each, fully paid up, were allotted upon exercise of vested options pursuant to the Employees Stock Options Scheme, 2011 and Share Based Incentive Plan 2019, resulting in an increase in the paid-up share capital by Rs. 8,000 (previous year Rs. Nil) and securities premium account by Rs. 0.54 crores (previous year Rs. Nil). 8. The Group operates exclusively in one reportable business segment i.e., Pharmaceuticals . 9. The Financial Results are available for investors at on the company's website www.ajantapharma.com, www.nseindia.com and www.bseindia.com. 10. Previous period figures have been re-grouped / re-classified wherever necessary, to confirm to current period’s classification in order to comply with the requirements of the amended Schedule III to the Companies Act, 2013 effective 1st April 2021. Single segment 2021-04-01 2021-09-30 Unaudited Consolidated 16327900000.00 621700000.00 16949600000.00 3613300000.00 745900000.00 -320300000.00 3180700000.00 19100000.00 624200000.00 4278000000.00 12140900000.00 4808700000.00 0.00 4808700000.00 1147100000.00 -35300000.00 1111800000.00 0.00 3696900000.00 0.00 0.00 0.00 0.00 3696900000.00 -65800000.00 3631100000.00 0.00 0.00 3631100000.00 0.00 173900000.00 2 42.72 42.72 0.00 0.00 42.72 42.72 Other Expenses 2296700000.00 Other Expenses 4278000000.00 19100000.00 -206400000.00 -800800000.00 0.00 116500000.00 0.00 7600000.00 80800000.00 0.00 -737700000.00 0.00 59400000.00 0.00 624200000.00 40000000.00 -31800000.00 25700000.00 215600000.00 -1600000.00 -86200000.00 0.00 7900000.00 1400000.00 -221900000.00 0.00 0.00 100000.00 0.00 0.00 -903900000.00 3904800000.00 0.00 0.00 0.00 1156600000.00 0.00 2748200000.00 0.00 0.00 1252300000.00 2777400000.00 0.00 0.00 0.00 250100000.00 157500000.00 758200000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 7900000.00 0.00 266300000.00 0.00 -2101700000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -5800000.00 0.00 0.00 64800000.00 0.00 19100000.00 0.00 0.00 -89700000.00 556800000.00 23300000.00 580100000.00 1775100000.00 2355200000.00